Viridian Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€261.69K - Cost of goods sold
€0.00 - Gross profit
€156.16K - SG&A expenses
€57.75M - R&D expenses
€261.33M - EBITDA
-€292.25M - D&A
€414.41K - EBIT
-€318.82M - Interest expenses
€2.54M - EBT
-€295.20M - Tax expenses
€0.00 - Net income
-€295.20M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€4.44M - Changes in working capital
-€3.17M - Operating cash flow
-€265.18M - Capex
€459.03K - Other investing cash flow
€0.00 - Net investing cash flow
€24.19M - Total cash dividends paid
€0.00 - Issuance of common stock
€233.67M - Debt repayment
€0.00 - Other financing cash flow
€15.60M - Net financing cash flow
€249.27M - Foreign exchange effects
€0.00 - Net change in cash
€8.29M - Cash at end of period
€100.66M - Free cash flow
-€264.72M
Balance sheet
- Cash and cash equivalents
€100.66M - Cash and short-term investments
€483.36M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€13.21M - Total current assets
€496.57M - Property, plant & equipment
€2.63M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€434.15K - Total non-current assets
€3.07M - Total assets
€499.63M - Accounts payable
€7.31M - Short-term debt
€7.71M - Other current liabilities
€29.85M - Total current liabilities
€45.12M - Long-term debt
€10.60M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€1.78M - Total non-current liabilities
€12.50M - Total liabilities
€57.62M - Common stock
€700.99K - Retained earnings
-€1.02B - Other equity
€59.20K - Total equity
€442.02M - Total liabilities and shareholders' equity
€499.63M
Company information
- Market capitalization
€997.28M - Employees
143 - Enterprise Value
€1.22B
Company ratios
- Gross margin
-
59.7% Much better than peer group: -72,533,636,981,793.8% - EBITDA margin
-
-111,677.4% Much better than peer group: -398,838,547,742,291.2% - EBIT margin
-
-121,831.1% Much better than peer group: -402,561,870,012,965.3% - EBT margin
-
-112,806.9% Much better than peer group: -402,084,158,808,968.3% - Net margin
-
-112,806.9% Much better than peer group: -402,084,158,809,063.0% - ROE
-
-66.8% Much worse than peer group: 3.0% - ROA
-
-59.1% Even with peer group: -55.1% - Asset turnover
-
0.1% Worse than peer group: 7.1% - FCF margin
-
-101,507.9% Much better than peer group: -335,024,120,436,795.3% - FCF yield
-26.6% - Efficiency ratio
111,777.4% - Net sales per employee
-
€1.83K - Net income per employee
-
-€2.06M